INVION LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 AUD | -16.67% |
|
0.00% | 0.00% |
| May. 08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
| Mar. 05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 21.21M | - | - | - | - | - | |
| 44.96B | - | |||||
| 42.65B | ||||||
| 41.85B | ||||||
| 29.04B | ||||||
| 26.08B |
- Stock Market
- Equities
- IVX Stock
- Charts Invion Limited
- Sector Chart